Laura A. Williams - 08 Jan 2026 Form 4 Insider Report for ARDELYX, INC. (ARDX)

Role
Chief Patient Officer
Signature
/s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams
Issuer symbol
ARDX
Transactions as of
08 Jan 2026
Net transactions value
-$299,400
Form type
4
Filing time
09 Jan 2026, 18:59:45 UTC
Previous filing
25 Nov 2025
Next filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Williams Laura A Chief Patient Officer C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM /s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams 09 Jan 2026 0001869194

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARDX Common Stock Options Exercise $49,500 +50,000 +14% $0.9900 409,896 08 Jan 2026 Direct
transaction ARDX Common Stock Sale $348,900 -50,000 -12% $6.98 361,563 08 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARDX Stock Option (Right to Buy) Options Exercise $0 0 0% $0.000000 62,000 08 Jan 2026 Common Stock 50,000 $0.9900 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades in prices ranging from $6.97 to $7.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2 Reflects the adjusted total which includes the purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025.
F3 The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.